




Compass

Guiding you along the way.

# Comprehensive support for your patients on JUXTAPID



<sup>a</sup>Applicants with federal and state government insurance such as Medicare, Medicaid, VA/DoD, and TRICARE are not eligible.

<sup>b</sup>This program is operated by Aegerion Pharmaceuticals, Inc. and may be modified at any time without notice.

<sup>c</sup>Subject to other eligibility criteria.



To speak with a Compass Care Manager, call 1-85-JUXTAPID (1-855-898-2743), Monday through Friday, 8 AM to 7 PM ET.

Please see Important Safety Information, including Boxed Warning, on page 7, and accompanying full Prescribing Information.

**Juxtapid**  
(lomitapide) capsules



**Compass**

Guiding you along the way.

# Tap into insurance support as soon as you prescribe JUXTAPID

Our team is committed to helping ensure that your patients have access to JUXTAPID. Compass Care Managers are available to provide the information you need to get your patients started.



## Benefits investigation assistance

- We will verify if your patient's insurance covers JUXTAPID
- You will be notified if additional steps are required for coverage (ie, prior authorization)



## Prior authorization support

- We can walk you through the prior authorization process, ensure that your office understands what information and forms are needed, and follow up on the status of existing submissions
- We can also provide a sample letter of medical necessity to help with the process



## Information about coverage appeals

- If coverage is denied, we'll help you understand the steps involved to appeal an initial coverage denial and follow up on the status of existing appeals
- We can also provide a sample letter of appeal for a denied claim to help with the process



**To speak with a Compass Care Manager, call 1-85-JUXTAPID (1-855-898-2743), Monday through Friday, 8 AM to 7 PM ET.**

# Help your patients cover the cost of JUXTAPID

We aim to make JUXTAPID affordable for patients by offering financial assistance to eligible patients. A Compass Care Manager will help determine which programs are best suited for your patients based on eligibility.



## Co-pay assistance<sup>a,b</sup>

Help your eligible commercially insured patients obtain **100% coverage of their monthly out-of-pocket costs** (up to an annual maximum) for JUXTAPID regardless of their financial status and whether they are new to JUXTAPID or already on therapy. There are no income requirements.



## Free drug assistance<sup>a,b</sup>

Help your patients **access JUXTAPID for free** if they are uninsured or underinsured (eg, have reached their insurance cap or have insurance that will not cover their JUXTAPID treatment).<sup>c</sup>

We can also help your uninsured patients explore other insurance plan options.

## Third-party patient assistance programs

Are your patients insured through Medicare, Medicaid, or any other state government insurance? We can refer them to alternative independent financial assistance programs. These types of programs may be able to provide financial assistance to eligible patients.

<sup>a</sup>Applicants with federal and state government insurance such as Medicare, Medicaid, VA/DoD, and TRICARE are not eligible.

<sup>b</sup>This program is operated by Aegerion Pharmaceuticals, Inc. and may be modified at any time without notice.

<sup>c</sup>Subject to other eligibility criteria.

Please see Important Safety Information, including Boxed Warning, on page 7, and accompanying full Prescribing Information.





**Compass**

Guiding you along the way.

# Start your patients off right and keep them motivated to stay on track



## In-person HoFH and JUXTAPID education

A Compass Patient Education Manager can provide one-on-one education on how to manage HoFH (homozygous familial hypercholesterolemia), information on how JUXTAPID works, and steps to get started. This education can take place in person or by phone and includes guidance, tips, and tools to help your patients be successful on their treatment plan.



## Individualized nutrition counseling

A dedicated Compass Registered Dietitian can consult with your patients over the phone to personalize a low-fat eating plan that works for them. They'll learn how to create a low-fat eating plan with their food preferences, as well as how this plan differs from a heart-healthy eating plan. They'll also learn how to use all the information and tools that Compass provides to help them stay on track.

## Ongoing communication

Check-in, follow-up, and refill reminder calls are available to help patients stay on JUXTAPID therapy.



**To speak with a Compass Care Manager, call 1-85-JUXTAPID (1-855-898-2743), Monday through Friday, 8 AM to 7 PM ET.**

# Utilize key pharmacy services to fulfill your patient's prescription



You and your patients have access to key pharmacy services so your patients can successfully start—and stay—on JUXTAPID.

- ✓ Direct-to-patient medication and supplies shipments
- ✓ Assistance with medication replacement if it is lost or damaged
- ✓ Help with JUXTAPID refills
- ✓ 24/7 pharmacist and nurse hotline in the event of an emergency
- ✓ Free nutritional supplements

Please see Important Safety Information, including Boxed Warning, on page 7, and accompanying full Prescribing Information.

**Juxtapid**  
(lomitapide) capsules



**Compass**

Guiding you along the way.

# Receive assistance with JUXTAPID REMS enrollment



**Because of the risk of hepatotoxicity, JUXTAPID is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the JUXTAPID REMS Program.**

Before you can write a prescription for JUXTAPID, you must first become JUXTAPID REMS-certified.

## Follow these simple steps to become JUXTAPID REMS-certified:

- 1 Contact your Aegerion Rare Disease Manager (RDM) to connect you with necessary resources.
- 2 Review the JUXTAPID Prescribing Information and Prescriber Training Module available at [juxtapidremsprogram.com](http://juxtapidremsprogram.com).
- 3 Complete, sign, and submit the one-time online JUXTAPID REMS Program Prescriber Enrollment Form at [juxtapidremsprogram.com](http://juxtapidremsprogram.com).

### Compass can:

- ✓ Answer your questions related to the JUXTAPID REMS Program
- ✓ Direct you to the necessary materials and resources
- ✓ Process your completed Prescriber Enrollment Form



**To speak with a Compass Care Manager, call 1-85-JUXTAPID (1-855-898-2743), Monday through Friday, 8 AM to 7 PM ET.**

# Indication and Important Safety Information

**INDICATION:** JUXTAPID® (lomitapide) capsules is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia (HoFH).

**LIMITATIONS OF USE:** The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH. The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined.

## **WARNING: RISK OF HEPATOTOXICITY**

**JUXTAPID can cause elevations in transaminases. In the JUXTAPID clinical trial, 10 (34%) of the 29 patients treated with JUXTAPID had at least one elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST)  $\geq 3\times$  upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR), or alkaline phosphatase.**

**JUXTAPID also increases hepatic fat, with or without concomitant increases in transaminases. The median absolute increase in hepatic fat was 6% after both 26 and 78 weeks of treatment, from 1% at baseline, measured by magnetic resonance spectroscopy. Hepatic steatosis associated with JUXTAPID treatment may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis.**

**Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT and AST regularly as recommended. During treatment, adjust the dose of JUXTAPID if the ALT or AST are  $\geq 3\times$  ULN. Discontinue JUXTAPID for clinically significant liver toxicity.**

**Because of the risk of hepatotoxicity, JUXTAPID is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the JUXTAPID REMS Program.**

**CONTRAINDICATIONS:** JUXTAPID is contraindicated in pregnancy, concomitant administration of moderate or strong CYP3A4 inhibitors, and moderate or severe hepatic impairment or active liver disease including unexplained persistent elevations of serum transaminases.

## **WARNINGS AND PRECAUTIONS**

JUXTAPID can cause elevations in transaminases and hepatic steatosis. Although cases of hepatic failure have not been reported, JUXTAPID could induce steatohepatitis, which can progress to cirrhosis over several years. Modify the dose of JUXTAPID if elevations of transaminases are observed and discontinue JUXTAPID for persistent or clinically significant elevations. If transaminase elevations are accompanied by clinical symptoms of liver injury, increases in bilirubin  $\geq 2\times$  ULN, or active liver disease, discontinue treatment with JUXTAPID and identify the probable cause. Use JUXTAPID with caution when co-administered with agents known to be hepatotoxic. Alcohol may increase levels of hepatic fat and induce or exacerbate liver injury. Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment. During the first year, measure liver-related tests (ALT and AST, at a minimum) prior to each increase in dose or monthly, whichever occurs first. After the first year, do these tests at least every 3 months and before any increase in dose.

JUXTAPID may cause fetal harm when administered to a pregnant woman. Females of reproductive potential should have a negative pregnancy test before starting JUXTAPID and should use effective contraception during therapy.

JUXTAPID may reduce the absorption of fat-soluble nutrients. Patients treated with JUXTAPID should take daily supplements that contain 400 IU vitamin E and at least 200 mg linoleic acid, 210 mg alpha-linolenic acid, 110 mg eicosapentaenoic acid, and 80 mg docosahexaenoic acid.

Gastrointestinal adverse reactions are common and may lead to treatment discontinuation. To reduce risk, patients should adhere to a low-fat diet supplying  $<20\%$  of energy from fat and JUXTAPID should be increased gradually.

CYP3A4 inhibitors increase exposure to JUXTAPID. Strong and moderate CYP3A4 inhibitors should not be used with JUXTAPID. JUXTAPID dosage should not  $>30$  mg daily when used with weak CYP3A4 inhibitors.

Due to risk of myopathy with simvastatin or lovastatin, doses should be limited when taken with JUXTAPID.

JUXTAPID increases the plasma concentrations of warfarin. Patients taking warfarin should undergo regular monitoring of the INR, especially after any changes in JUXTAPID dosage.

Avoid use of JUXTAPID in patients with rare hereditary diseases of galactose intolerance.

**ADVERSE REACTIONS:** Most common adverse reactions ( $\geq 28\%$ ) were diarrhea, nausea, vomiting, dyspepsia, and abdominal pain.

**Please see accompanying full Prescribing Information.**





**Compass**

Guiding you along the way.

# Get your patients started with JUXTAPID

Follow the 3 simple steps below to get your patient started with JUXTAPID treatment.

## 1. Complete the one-time, online REMS training:

- Visit [juxtapidremsprogram.com](http://juxtapidremsprogram.com) and review the education materials
- Complete and submit the one-time online JUXTAPID REMS Program Prescriber Enrollment Form


## 2. Write the prescription:

- Complete, sign, and fax the JUXTAPID REMS Prescription Authorization Form to 1-885-898-2498

## 3. Enroll your patient in Compass, the JUXTAPID support program:

- Complete and sign the JUXTAPID Compass Enrollment Form
- Have your patient review and sign the 2 Compass Patient Authorizations
  - These authorizations enable Aegerion to receive the patient's personal and health information so that the Compass team can provide support services to your patient, such as insurance support, financial assistance, and nutritional counseling
- Fax the 2 completed and signed forms to 1-885-898-2498

If you have any questions, call  
1-85-JUXTAPID (1-855-898-2743),  
Monday through Friday, 8 AM to  
7 PM ET, to speak to a Compass  
Care Manager.



**Please see Important Safety Information, including Boxed Warning, on page 7, and accompanying full Prescribing Information.**

**Aegerion**<sup>®</sup>  
Pharmaceuticals

©2015 Aegerion Pharmaceuticals, Inc.  
JUXTAPID is a registered trademark and Compass is a trademark of Aegerion Pharmaceuticals, Inc.  
All rights reserved. JUX/US/223 10-15

  
**Juxtapid**<sup>®</sup>  
(lomitapide) capsules